Switching Medication to Treat Schizophrenia
Effectiveness of Switching Antipsychotic Medications
2 other identifiers
interventional
219
0 countries
N/A
Brief Summary
This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_4 schizophrenia
Started Jul 2001
Longer than P75 for phase_4 schizophrenia
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2001
CompletedFirst Submitted
Initial submission to the registry
September 3, 2002
CompletedFirst Posted
Study publicly available on registry
September 5, 2002
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2009
CompletedResults Posted
Study results publicly available
December 5, 2013
CompletedMay 15, 2026
April 1, 2026
7.7 years
September 3, 2002
September 27, 2013
April 23, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Number Who Discontinued Medication Within First 6 Study Months
Measured at Six Months
Secondary Outcomes (1)
Number of Participants Hospitalized
during first 6 months
Study Arms (2)
Stay on baseline medication prescribed
ACTIVE COMPARATORParticipants will continue taking medication prescribed at study entry: 1) either long-acting injectable haloperidol or fluphenazine, OR 2) two antipsychotic medications which might include a combination of any of the following: risperidone, olanzapine, ziprasidone, quetiapine, aripiprazole, or conventional (typical) antipsychotic medications.
Switch per study protocol
ACTIVE COMPARATORParticipants will change medications from medication prescribed at study entry, either: 1) long-acting injectable risperidone, OR 2) one of the two antipsychotic medications prescribed at baseline which may include any of the following: risperidone, olanzapine, ziprasidone, quetiapine, aripiprazole, or conventional (typical) antipsychotic medications.
Interventions
As prescribed by routine prescriber (not dictated by study protocol)
As prescribed by routine prescriber (not dictated by study protocol)
As prescribed by routine prescriber (not dictated by study protocol)
As prescribed by routine prescriber (not dictated by study protocol)
As prescribed by routine prescriber (not dictated by study protocol)
Eligibility Criteria
You may qualify if:
- SCID diagnosis of schizophrenia or schizoaffective disorder
- Partially remitted outpatients, defined as persons who have received clear symptomatic benefit from antipsychotic medication but remain symptomatic (due to lack of efficacy or inability to tolerate an efficacious dose) or suffer significant side effects
- Treatment with antipsychotic medications for at least 2 months
- Received at least 1 outpatient mental health service every 3 months for the past 6 months
You may not qualify if:
- Severe symptoms or side effects that indicate the necessity for a medication change
- Currently taking 3 or more antipsychotic medications for ongoing daily administration (PRN medications and mood stabilizers are allowable)
- Treatment with clozapine
- One or more nights spent in a psychiatric hospitalization within the past 3 months
- Received services from a crisis intervention program within the past 3 months
- Require placement in a skilled nursing facility as a result of a physical condition or disability
- Criminal charges pending (once charges clear, the person will be considered)
- Pregnant or breast feeding
- Contraindication to any of the medications to which the patient might be assigned
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (2)
Covell NH, McEvoy JP, Schooler NR, Stroup TS, Jackson CT, Rojas IA, Essock SM; Schizophrenia Trials Network. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. J Clin Psychiatry. 2012 May;73(5):669-75. doi: 10.4088/JCP.11m07074. Epub 2012 Mar 6.
PMID: 22480442RESULTEssock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH; Schizophrenia Trials Network. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011 Jul;168(7):702-8. doi: 10.1176/appi.ajp.2011.10060908. Epub 2011 May 2.
PMID: 21536693RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Nancy H. Covell, Ph.D.
- Organization
- NYSPI
Study Officials
- STUDY CHAIR
Susan M. Essock, PhD
Columbia University
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Director, CPI
Study Record Dates
First Submitted
September 3, 2002
First Posted
September 5, 2002
Study Start
July 1, 2001
Primary Completion
March 1, 2009
Study Completion
March 1, 2009
Last Updated
May 15, 2026
Results First Posted
December 5, 2013
Record last verified: 2026-04